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In this study, genistein, a selective protein tyrosine kinase (PTK) inhibitor, inhibited 
peripheral blood mononuclear cell (PBMC) proliferation and interleukin-2 production 
from cultures that were stimulated with phytohemagglutinin (PHA), phorbol 12 
myristate 13-acetate (PMA) plus A23187, or PHA plus PMA, and genistein effectively 
blocked the PHA plus IL-2-induced PBMC proliferation. Further. we also found that 
genistein inhibited LTB, production from A23187-stimulated cultures whereas H-7, a 
PKC inhibitor, had no effect on LTB, production. Our results suggest that PTK may be 
necessary for the synthesis of LTB,. o 1991 Academic press. LX. 
INTRODUCTION 
The leutrokrienes are formed by the oxygenation of arachidonic acid (AA)3 at 
the C-5 position (1). This process results in the production of an unstable epoxide, 
leukotriene AA, which can be converted enzymatically by hydrolysis to LTB, or 
to LTC, with the addition of glutathione (1). Reports from several laboratories 
show that LTB, exerts significant and diversified effects on mononuclear cells. 
LTB, was shown to induce suppressor cell activity (2-4) or to enhance lympho- 
cyte proliferation (4-6). Further, roles for lipoxygenase metabolites of AA in IL-1 
and IL-2 production were described (7-9). 
Protein tyrosine kinases (PTK) are among the molecules that have been impli- 
cated in the control of cell growth and differentiation. High levels of PTK activity 
have been described in normal and transformed T cells and monocytes of humans 
(10-13). T cells stimulated by mitogenic lectins have been shown to cause in- 
creased phosphorylation of membrane (12) and cytosolic (14) proteins on tyrosine 
residues. suggesting a role for PTK activity in T-cell activation or proliferation. 
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We and others have shown that genistein, an isoflavonoid compound, specifically 
inhibits PTK (15-17). 
Protein kinase C (PKC) is a ubiquitous enzyme involved in the signal transduc- 
lion of cell proliferation (18). Addition of PHA to human T cells resulted in a 
rapid, transient association of PKC with the particulate fraction (19). Using H-7. 
a specific PKC inhibitor, several laboratories have shown the role of PKC in the 
proliferation of T cells or T cell lines, IL-2 production. and IL-2R expression 
(20-23). Further, it was shown that H-7 potentiated the release of arachidonic acid 
from human neutrophils (24). 
In the present study we designed experiments to compare the effects of 
genistein and H-7 on A23187-stimulated LTB, production and the effects of 
genistein on PBMC proliferation and IL-2 production. We found that genistein 
inhibited LTB4 production, but that H-7 had no measurable effect on LTB4 pro- 
duction. Genistein inhibited [‘Hlthymidine incorporation of PBMC in a dose- 
dependent manner. Addition of exogenous lL-2 had no effect in reversing the 
inhibition caused by genistein. Our results suggest that PTK but not PKC may 
play an important role in regulating LTB, production. 
MATERIALS AND METHODS 
Peripherul blood mononuclear cell isolation. Peripheral venous blood was ob- 
tained from each subject into syringes containing preservative-free heparin. Pe- 
ripheral blood mononuclear cells were isolated by Ficoll-Hypaque centrifugation 
(22) was washed three times with phosphate-buffered saline (PBS). The PBMC 
were then used in the assays as described below. 
Cell cultures. PBMC at lo5 cells in 200 t.~l of RPM1 1640 medium supplemented 
with 10% fetal calf serum, L-glutamine, and penicillin-streptomycin were cultured 
in microtiter plates as described (22). Briefly, PHA, PMA, calcium ionophore 
(A23187), or genistein was added directly to the wells upon initiation of the cul- 
tures. In some experiments, genistein was added at various times after the initi- 
ation of cell cultures. Tritiated thymidine was added to the cell cultures 66 hr after 
their initiation. and the cells were harvested at 72 hr onto glass wool filter paper 
and counted in a liquid scintillation counter. All cultures were performed in trip- 
licate. The percentage inhibition caused by genistein was calculated and results 
are expressed as 
I-A-C 
percentage inhibition = 
B-C 
x 100. 
in which A is the cpm in cultures with genistein, B is the cpm in cultures without 
genistein, and C is the cpm in nonstimulated cultures. 
PBMC at 1 x lo6 cells in 1 .O ml medium were cultured in 12 x 75mm culture 
tubes for measuring interleukin-2 (IL-2) production. PHA, PMA, A23187, or 
genistein was added at the initiation of cell cultures. IL-2 activity was measured 
from 24-hr culture supernatants by using CTLL-2 cells as described previously 
(22). 
Radioimmunoassay fur LTB,. PBMC at 1 x lO‘?ml were incubated with A23817 
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and/or genistein or H-7 for 30 min at 37OC, and supematants were assayed for 
LTB, directly or after extraction using radioimmunoassay as described previously 
(25). The results were calculated using PC software (Quickcal Q, Arbor Immu- 
nalysis, Ann Arbor, MI). The RIA employed (Amersham, Arlington Heights, IL) 
was sensitive to 1.6 pg/ml and had the following cross-reactivities: LTC, and 
LTD, <0.05%: 5, 12-, and 15HETE <0.05%; and 20-OH-LTB4 0.4%. 
Culture additives. PHA was purchased from Burroughs-Wellcome (Research 
Triangle Park, NC). A23187 was purchased from Calbiochem (LaJolla, CA). PMA 
was purchased from Sigma Chemical Co. (St. Louis, MO). Both A23187 and PMA 
was dissolved in DMSO. Genistein was obtained from Bio-Mol (Philadelphia, PA) 
and dissolved in DMSO at 10 mg/ml and stored at - 20°C. PKC inhibitor H-7 was 
purchased from Seikagaku America Inc. (St. Petersburg, FL) and dissolved in 
distilled water to yield a 10 n&f stock solution. All culture additives were appro- 
priately diluted in RPM1 1640 medium immediately before use. 
RESULTS 
Figure 1 presents the results of experiments with three subjects, measuring the 
dose-response of genistein on [‘HJthymidine incorporation in PHA-stimulated 
PBMC proliferation. Genistein inhibited PBMC proliferation in a dose-response 
manner. Further, we found that genistein inhibited PMA plus A23187-stimulated 
PBMC proliferation (Fig. 2). In this study, PMA or A23187 by itself did not cause 
any proliferation of PBMC (data not shown). 
Next, we asked whether genistein was inhibiting PBMC proliferation via inhi- 
bition of IL-2 production from these cultures. Genistein inhibited IL-2 production 
from PHA plus PMA or PMA plus A23187-stimulated cultures (Table 1). Further, 
we were interested to see whether IL-2 could reverse the genistein effect on 
PHA-stimulated PBMC proliferation. The presence of exogenous IL-2 (25 U/ml) 
caused an increased proliferation of PBMC and had no effect in reversing the 
inhibitory effect of genistein (Table 2). 



















FIG. I. Effect of genistein on PHA-stimulated PBMC proliferation. PBMC were cultured with PHA 
and/or genistein (various concentrations) for 3 days to measure [3H]thymidine incorporation as de- 
scribed under Materials and Methods. Culture additives are used as follows: PHA, 2.0 pg/ml; 
genistein. 1 .O. 5.0, and 10.0 &ml. Data represent mean 5 SEM of three experiments using different 
donors. 
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FIG. 2. Inhibition of PMA plus A23187-stimulated PBMC proliferation. PBMC were cultured for 3 
days to measure [3H]thymidine incorporation. Culture additives are used at the following concentra- 
tions: PMA. 10.0 &ml: A23187, 0.5 @/ml. Data represent mean -+ SD of two experiments using 
different donors. 
[3H]thymidine incorporation, when 10.0 t.@nl of genistein was added to the PHA- 
stimulated PBMC at various times after culture initiation. Genistein inhibited the 
late stage activation of PBMC proliferation (Fig. 3). 
Because LTB4 has been described as playing an important role in IL-2 produc- 
tion (9), we investigated whether genistein at the same concentration that inhib- 
ited IL-2 synthesis had any effect on LTB, production from PBMC cultures. Data 
presented in Table 3 show the levels of LTB, from the supernatants of PBMC 
cultured with A23187 and/or genistein was measured by RIA. A23187 caused an 
increase in LTB4 production, and genistein inhibited >50% of LTB, production. 
Recently, we have shown that H-7 (10 pJ4) inhibited IL-2 production from PHA 
plus PMA-stimulated human T cells (22). However, in the present study. H-7 at 
the same concentration showed no effect on A23187-stimulated LTB, production 
(Table 3). 
Because of these inhibitory effects by genistein in cell cultures, we measured 
PBMC viabilities. Genistein at concentrations that inhibited PBMC proliferation, 
TABLE I 
EFFECTOF GENISTEIN ON IL-2 PRODUCTION FROM PBMC CULTURES 
IL-2 production (U/ml)” 
Culture conditions Expt I Expt 2 
PBMC co. I 0.1 
PBMC + PHA + PMA 15.0 13.2 
PBMC + PHA + PMA + genistein co. 1 co. 1 
PBMC + PMA + A23187 39.0 34.0 
PBMC + PMA + A23187 + genistein 7.0 3.5 
a Results are expressed as units of interleukin-2 produced from 24-hr culture supernatants from two 
different experiments using different donors. Similar results were obtained using three other experi- 
ments using different donors. Culture additives are used at the following concentrations: PHA, 10.0 
&ml; PMA. 10.0 &ml; A23187. 0.5 PM/ml: genistein. 10.0 &ml. 
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TABLE 2 
EFFECT OF GEN~STEIN ON PHA-STIMULATED [‘HITHYMIDINE INCORPORATION IN THE PRESENCE 
OR ABSENCE OF INTERLEUKIN-2 
Counts per minuteC 
PHA GTN” IL-2* 
- - - 
+ - - 
+ + - 
+ - + 
+ + + 
“ Genistein was added at 10.0 &ml. 
b Purified human IL-2 was added at 25 U/ml. 
’ Results are expressed as counts per minute from triplicate determinations of each experiment 
using different donors. Similar results were obtained using two other experiments using different 
donors. 
Expt I Expt 2 Expt 3 
1,281 1.712 I.828 
20.6% 16.342 22,876 
4.383 2,862 2.189 
47,807 29.572 30,473 
9,093 5,198 8,678 
IL-2 synthesis, and LTB4 production from stimulated cultures had no effect on 
PBMC viabilities, as measured by the trypan blue dye exclusion test (Table 4). 
DISCUSSION 
The results of the present investigation can be summarized as follows. 
Genistein, a selective PTK inhibitor, inhibited PHA or PMA plus A23187- 
stimulated PBMC proliferation; at the same concentration, it also inhibited IL-2 
synthesis from PHA plus PMA or PMA plus A23187-stimulated lymphocytes; 
further, it inhibited A23187-stimulated LTB, production. 
T-cell proliferation is an autocrine process characterized by the sequential ex- 
pression of IL-2R. synthesis and secretion of IL-2. and finally interaction of the 
growth factor with its receptor (26). T-cell receptor (TCR) activation by antigen, 
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FIG. 3. Kinetic study of the inhibitory effect of genistein (10.0 kg/ml) on PHA-stimulated human 
PBMC proliferation. PBMC were cultured for 3 days to measure 13H]thymidine incorporation as 
described under Materials and Methods. Genistein (IO.0 &ml) was added at various times after 
initiation of cultures. Data represent mean t SD of two experiments using different donors. 
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No[e. Results are expressed as units of LTB, produced in culture supernatants. from four different 
donors. Similar results were obtained using six other experiments using different donors. Culture 
additives are used as follows: A23187. I.0 pLM/ml: GTN 10.0 p&ml: H-7. 10.0 t&I/ml. 
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activity, as demonstrated by observing TCR-5 chain tyrosine phosphorylation 
(27-30). Considerable interest has developed regarding TCR activation of tyrosine 
kinase activity, because there is substantial evidence to implicate tyrosine-kinase 
in the control of mitogenesis, cell cycle growth, and development (31, 32). Re- 
cently, using genistein, we have shown the inhibition of PTK- (IS), PHA-, and 
anti-CD, mAb-induced TCR-5 phosphorylation (33). Similar results were reported 
by Mustelin rt al. (17). Further, they found that genistein also inhibited phorbol 
ester plus A23 187-stimulated T-cell proliferation (cited as unpublished observa- 
tion in Ref. (17)). Our data are consistent and confirm their findings (Fig. 2). One 
could argue that genistein may be nonspecifically inhibiting PKC, thus causing the 
immunosuppression reported herein. We found that genistein at this concentra- 
tion (10.0 pg/ml) had no effect on CD,, (33), the early activating antigen induced 
by PMA (34). Similarly, cyclosporin A was shown not to have any effect on 
PMA-induced CD,, (35). but CsA is still a very important immunosuppressive 
agent (36). 
The role of lipoxygenase products of AA in lL-1 and IL-2 production have been 
described (7-9). Using lipoxygenase inhibitors, Dinarello et al. (7) reported a 
decrease in IL- 1 production. Another laboratory reported an increase in IL- 1 and 
IL-2 synthesis from human monocyte and T-cell cultures in the presence of ex- 
ogenous LTB4 and LTD, (8, 9). Moreover, AA has already been proposed as 
another potential second messenger in T lymphocytes (37). The data presented in 
this study show that genistein at the concentration that inhibited LTB4 synthesis 
also inhibited IL-2 production (Tables 1 and 3). Earlier, we showed that genistein 
TABLE 4 
EFFECT OF GENISTEIN ON PBMC VIABILITIES 
% Viable cells” 
Culture additives Expt I Expt 2 Expt 3 
PHA 79 80 75 
PHA + GTN (IO.0 &ml) 78 80 73 
” Cell viabilities were determined using the trypan blue dye exclusion test from 48-hr cultures of 
three experiments using different donors. 
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at this concentration (10.0 pg/ml) inhibited the mRNA for IL-2 from PHA plus 
PMA or PMA plus OKT,-stimulated human T-cell cultures (33). Although the role 
of PKC in T-cell proliferation is well documented, its role in the AA metabolite(s) 
pathway is not clear. Activation of PKC apparently is not sufficient to induce 
LTB,, but its action appears to be required to couple a rise in intracellular Ca*+ 
to induce LTB, (38). However, H-7, a PKC inhibitor, was shown to enhance the 
A23187-stimulated release of AA from human neutrophils (24). Gouvello et al. 
(39) showed that PMA neither stimulated nor modulated CD,-induced AA release, 
and they suggested that CD, triggering stimulates phospholipase AZ activity in T 
lymphocytes via an extracellular Ca*+ -dependent and PLC- and PKC- 
independent mechanism (39). The data presented in Table 3 show that PKC has no 
role in regulating LTB, synthesis, although H-7 inhibited PHA-induced IL-2 pro- 
duction and cell proliferation (data not presented). Preliminary data obtained from 
another study show that endogenous LTB, appears necessary in regulating IL-2 
production at the message level (D. Atluru, unpublished data). 
The kinetic study of the addition of genistein to the PHA-stimulated cell cul- 
tures showed that genistein, when added at any time, still inhibited lymphocyte 
proliferation (Fig. 3). Similar results were reported by Mustelin et al. (17), where 
they found that genistein inhibited the early and late stage activation of human 
T-cell proliferation. Further, we found that genistein inhibited the purified human 
T-cell proliferation of both early and late stage activation (data not presented). 
These inhibitory effects caused by genistein were not due to its toxic effects on 
PBMC (Table 4). Genistein was shown to inhibit the mammalian DNA topio- 
somerase II (40), and we recently showed that genistein is able to block anti-CD,, 
monoclonal antibody-stimulated human T-cell proliferation (41). which is resistant 
to CsA or FK-506 (41-43). Preliminary data obtained from our laboratory show 
that CsA has no effect on LTB, synthesis (S. Atluru, unpublished data). 
In summary, our data suggest that PTK may be necessary to regulate LTB4 
production. These data also show that the PTK inhibitor, genistein, may be used 
as an immunosuppressive or anti-inflammatory agent. 
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